What is the Need for Prostatic Biomarkers in Prostate Cancer Management?
Publisher DOI
PubMed ID
26267226
Abstract
Discriminating patients with a low risk of progression from those with lethal prostate cancer is one of the main challenges in prostate cancer management. Indeed, such discrimination is essential if we aim to avoid overtreatment in men with indolent disease and to improve survival in those men with lethal disease. We are reporting on the current literature on such prognostic tools that are now available, their clinical role and their limitations in individualizing care. There is an urgent need to incorporate such genomic tools into new platform-based clinical trial structures to further develop and validate prognostic and predictive biomarkers and provide prostate cancer patients with an effective and cost-efficient access to new drugs in the setting of personalized treatment.
Date Issued
2015-10
Publication Type
Article
Subject(s)
Language(s)
en
Author(s)
Joniau, Steven | |
Moschini, Marco | |
Tombal, Bertrand | |
Karnes, R Jeffrey |
Additional Credits
Journal
Current urology reports
Publisher
Current Science
ISSN
1527-2737
Access(Rights)
open.access